Type 1 diabetes incidence among children under 18 years of age in Israel increased by 6% per annum between 2000 and 2008. Among children under 5 years of age, it increased by 104% in 6 years. The authors suggested that viral infections could be one of the factors in the disease, which mean that rotavirus vaccination might reduce the risk of diabetes. It turned out, however, that there were 7.4 times more vaccinated than unvaccinated among type 1 diabetes patients.
Analysis of data from a Hib vaccine clinical trial in Finland (116,000 children). Hib vaccine increases the risk of juvenile diabetes by 26%. Diabetes occurred 38 months after vaccination.
The vaccine was also tested on mice prone to diabetes. Vaccinated mice developed diabetes significantly more often.
Other studies found a similar increased risk of diabetes, but since these studies were small, the results were statistically insignificant.
Just this side effect alone (increased risk of juvenile diabetes) exceeds the benefit of the vaccine, which should prevent 7 death cases and 7-26 disability cases in 100,000 of those vaccinated. For every child saved from Hib, there will be four people with diabetes.
After the introduction of Hib vaccination in the USA and England the diabetes incidence increased dramatically, especially among children under 4 years of age.
The authors conclude that the potential harm from the vaccine outweighs the potential benefit.
Vaccine studies are based on the theory that the benefits of vaccination significantly exceed the risk of long-term side effects, and therefore long-term safety studies are not necessary.
We found that just the increased risk of one of the side effects (diabetes) already exceeds the decreased risk of meningitis. We believe that the public should be informed that vaccines could cause long-term complications. It will cause the public to demand more adequate safety studies before introducing vaccines, which in turn will lead to development of safer vaccines.
Hib vaccine increases the risk of development to GAD antibodies by 5.9 times, and the risk of IA-2 antibodies development by 3.4 times, which are considered to be autoimmune markers for the development of type-1 diabetes.